Abbott Expands PFA Portfolio with CE-Marked TactiFlex Duo Catheter for Complex AFib Cases

Event summary

  • Abbott received CE Mark approval for its TactiFlex Duo Ablation Catheter on January 20, 2026, enabling treatment of complex atrial fibrillation (AFib) cases in Europe.
  • The catheter combines radiofrequency and pulsed field ablation (PFA) energies, offering physicians flexibility during procedures.
  • First commercial cases using TactiFlex Duo were completed in the European Union this week.
  • The approval follows Abbott's Volt PFA System approvals in the U.S. and Europe in 2025, strengthening its PFA portfolio.

The big picture

Abbott's TactiFlex Duo Catheter represents a strategic expansion of its pulsed field ablation (PFA) technology, addressing the growing need for tailored treatments in complex AFib cases. With approximately eight million Europeans over 65 living with AFib—a number expected to double by 2060—the approval strengthens Abbott's position in a market increasingly focused on minimally invasive, personalized cardiac care. The company's growing PFA portfolio, including the Volt PFA System, underscores its commitment to advancing electrophysiology solutions.

What we're watching

Regulatory Progress
Whether Abbott can secure FDA approval for TactiFlex Duo, following its Breakthrough Device Designation for ventricular tachycardia treatment.
Market Penetration
The pace at which TactiFlex Duo gains adoption in Europe, particularly for complex AFib cases.
Competitive Dynamics
How Abbott's expanded PFA portfolio positions it against competitors in the cardiac ablation market.